Undifferentiated Symptoms

Undifferentiated Symptoms UK Medical PG Question 1: A 72-year-old man with chronic kidney disease stage 4 (eGFR 24 ml/min/1.73m²), type 2 diabetes, hypertension, and gout presents for medication review. His current medications include: metformin 1g twice daily, gliclazide 80mg twice daily, ramipril 10mg once daily, amlodipine 10mg once daily, aspirin 75mg once daily, atorvastatin 80mg once daily, allopurinol 100mg once daily, and omeprazole 20mg once daily. His HbA1c is 58 mmol/mol, and he reports intermittent episodes of feeling 'shaky and sweaty'. Which medication requires MOST urgent modification?

• A. Allopurinol should be increased to 300mg daily for adequate urate control
• B. Metformin should be stopped immediately due to risk of lactic acidosis (Correct Answer)
• C. Ramipril should be reduced due to advanced chronic kidney disease
• D. Gliclazide should be reviewed and reduced due to hypoglycaemia risk
• E. Aspirin should be stopped as cardiovascular protection is inadequate at this dose

Undifferentiated Symptoms Explanation: ***Metformin should be stopped immediately due to risk of lactic acidosis***- **Metformin** is primarily cleared by the kidneys and is **contraindicated** when the **eGFR falls below 30 ml/min/1.73m²** (CKD Stage 4). The patient's eGFR is 24.- Continued use in this setting significantly increases the risk of **metformin-associated lactic acidosis (MALA)**, a severe and life-threatening metabolic emergency requiring urgent discontinuation.*Allopurinol should be increased to 300mg daily for adequate urate control*- Increasing **allopurinol** to 300mg in a patient with an **eGFR of 24 ml/min/1.73m²** is inappropriate and risky, as it can lead to severe toxicity, including **allopurinol hypersensitivity syndrome**.- The current dose of **100mg daily** is generally considered the maximum safe dose for patients with this level of **renal impairment**.*Ramipril should be reduced due to advanced chronic kidney disease*- **ACE inhibitors** like **ramipril** are often beneficial in CKD for **renoprotection** and blood pressure control, provided there is no acute kidney injury or severe hyperkalemia.- While renal function and electrolytes require close monitoring, discontinuing metformin due to the immediate and severe risk of **lactic acidosis** takes precedence.*Gliclazide should be reviewed and reduced due to hypoglycaemia risk*- The patient's symptoms of feeling "shaky and sweaty" are classic for **hypoglycaemia**, likely exacerbated by **gliclazide** accumulation due to reduced renal clearance.- While adjusting **gliclazide** is crucial to prevent further hypoglycaemic episodes, the immediate risk of **metformin-associated lactic acidosis** is a higher priority.*Aspirin should be stopped as cardiovascular protection is inadequate at this dose*- **Aspirin 75mg daily** is the standard and effective dose for **secondary prevention** of cardiovascular events, especially in patients with multiple risk factors like this gentleman.- There is no clinical indication to stop aspirin based on its efficacy at this dose, and doing so would remove a crucial component of his cardiovascular protection.

Undifferentiated Symptoms UK Medical PG Question 2: According to the Beers Criteria for potentially inappropriate medication use in older adults, which of the following medications should be avoided in elderly patients regardless of diagnosis or condition?

• A. Long-acting benzodiazepines such as diazepam and chlordiazepoxide (Correct Answer)
• B. Non-selective beta-blockers in patients with peripheral vascular disease
• C. First-generation antihistamines in patients with cognitive impairment
• D. Proton pump inhibitors when used for longer than 8 weeks
• E. Thiazide diuretics in patients with a history of gout

Undifferentiated Symptoms Explanation: ***Long-acting benzodiazepines such as diazepam and chlordiazepoxide*** - The **Beers Criteria** recommends avoiding these medications in all older adults due to their **long half-lives**, which lead to accumulation and prolonged effects. - Usage significantly increases the risk of **falls, fractures, cognitive impairment**, and motor vehicle accidents in the elderly population. *Non-selective beta-blockers in patients with peripheral vascular disease* - This is a **condition-specific** precaution rather than a general category for avoidance in all older adults regardless of diagnosis. - While they can theoretically worsen claudication, they are not listed as **potentially inappropriate medications** for all geriatric patients in the primary Beers list. *First-generation antihistamines in patients with cognitive impairment* - While these are generally avoided due to **anticholinergic effects**, the option specifies a condition (cognitive impairment) rather than a universal avoidance. - The Beers Criteria actually recommends avoiding all highly anticholinergic **first-generation antihistamines** for most older adults, but the long-acting benzodiazepine choice is the most definitive answer for universal avoidance in this context. *Proton pump inhibitors when used for longer than 8 weeks* - PPIs are listed under the Beers Criteria to be avoided beyond **8 weeks** of use due to risks of **Clostridioides difficile** infection and bone loss. - This is a **duration-specific** recommendation rather than a medication that must be avoided entirely regardless of the clinical situation or time frame. *Thiazide diuretics in patients with a history of gout* - This represents a **disease-drug interaction** where the medication may exacerbate a specific pre-existing condition by increasing **uric acid** levels. - Thiazides are not on the list of medications to be avoided in all elderly patients; they remain first-line therapy for **hypertension** in many older adults.

Undifferentiated Symptoms UK Medical PG Question 3: A practice pharmacist is conducting a quality improvement project on anticholinergic burden in elderly patients with multimorbidity. She identifies a 73-year-old man taking 12 medications with a total Anticholinergic Cognitive Burden (ACB) score of 6. His medications include amitriptyline 50mg nocte for neuropathic pain, tolterodine 4mg for overactive bladder, lansoprazole 30mg, co-codamol 30/500, atorvastatin, ramipril, bisoprolol, aspirin, and metformin. He reports feeling 'foggy-headed' and has had two falls. Which intervention would have the GREATEST impact on reducing anticholinergic burden?

• A. Switch tolterodine to mirabegron, a beta-3 agonist with no anticholinergic activity
• B. Replace amitriptyline with duloxetine for neuropathic pain management
• C. Stop lansoprazole as proton pump inhibitors contribute to cognitive impairment
• D. Address both amitriptyline and tolterodine simultaneously by switching to alternatives (Correct Answer)
• E. Reduce co-codamol dose as opioids can contribute to cognitive impairment

Undifferentiated Symptoms Explanation: ***Address both amitriptyline and tolterodine simultaneously by switching to alternatives*** - **Amitriptyline** and **tolterodine** are both high-burden drugs (ACB score of 3 each); replacing both is the most effective way to reduce the total **Anticholinergic Cognitive Burden (ACB)** score from 6 to near zero. - Addressing both medications directly targets the patient's symptoms of **cognitive impairment ('foggy-headed')** and **falls**, which are classic adverse effects of high anticholinergic exposure in the elderly. *Switch tolterodine to mirabegron, a beta-3 agonist with no anticholinergic activity* - Switching **tolterodine** alone would only reduce the ACB score by 3, leaving the patient with a still-significant burden from the **amitriptyline**. - While **mirabegron** is an excellent alternative for **overactive bladder** without anticholinergic effects, it does not address the neuropathic pain medication's contribution to the score. *Replace amitriptyline with duloxetine for neuropathic pain management* - Replacing **amitriptyline** with **duloxetine** (which has minimal to no anticholinergic activity) reduces the score by 3 but ignores the impact of **tolterodine**. - Although this is a clinically sound step for **neuropathic pain**, a singular drug change is less impactful than a comprehensive review of all high-ACB agents. *Stop lansoprazole as proton pump inhibitors contribute to cognitive impairment* - **Lansoprazole** (a proton pump inhibitor) does not contribute to the **Anticholinergic Cognitive Burden** score, so stopping it would not improve the ACB metrics. - While PPIs have other long-term risks, they are not the primary cause of **anticholinergic-mediated** delirium or falls in this scenario. *Reduce co-codamol dose as opioids can contribute to cognitive impairment* - **Co-codamol** (codeine/paracetamol) can cause sedation and falls due to its **opioid** component, but it does not carry a weight on the **ACB scale**. - Reducing the dose may help general alertness but will not lower the **anticholinergic-specific** burden that this quality improvement project aims to address.

Undifferentiated Symptoms UK Medical PG Question 4: A 74-year-old man attends for medication review. He has heart failure (LVEF 32%), atrial fibrillation, type 2 diabetes, stage 3b CKD (eGFR 36 ml/min/1.73m²), and benign prostatic hyperplasia. Current medications: bisoprolol 10mg, ramipril 10mg, furosemide 40mg, spironolactone 25mg, apixaban 5mg twice daily, metformin 1g twice daily, empagliflozin 10mg, finasteride 5mg, tamsulosin 400mcg, atorvastatin 80mg. Blood tests show potassium 5.4 mmol/L, sodium 134 mmol/L, urea 12.8 mmol/L, creatinine 168 μmol/L (stable). He reports good symptom control but occasional dizziness on standing. Which represents the BEST management approach?

• A. Stop spironolactone due to hyperkalaemia risk and continue other heart failure medications
• B. Reduce ramipril to 5mg daily to decrease potassium and improve renal function
• C. Stop empagliflozin as it may be contributing to hyperkalaemia and renal impairment
• D. Continue current regimen with close monitoring as benefits outweigh risks (Correct Answer)
• E. Stop tamsulosin as it may be causing orthostatic hypotension and reduce polypharmacy

Undifferentiated Symptoms Explanation: ***Continue current regimen with close monitoring as benefits outweigh risks*** - The patient is receiving the **'quadruple therapy'** for heart failure with reduced ejection fraction (HFrEF), which significantly reduces **mortality** and hospitalizations. - A potassium of 5.4 mmol/L is acceptable for transition to long-term monitoring as it remains **below 5.5 mmol/L**, and his creatinine/eGFR values are stable and within an acceptable range for these medications. *Stop spironolactone due to hyperkalaemia risk and continue other heart failure medications* - Guidance suggests keeping mineralocorticoid receptor antagonists (MRAs) unless potassium consistently **exceeds 5.5 mmol/L**, as they provide a crucial **survival benefit**. - Routine cessation for mild elevations prevents the patient from receiving life-prolonging **aldosterone blockade**. *Reduce ramipril to 5mg daily to decrease potassium and improve renal function* - Reducing the **ACE inhibitor** dose for a stable eGFR of 36 ml/min/1.73m² and mild hyperkalemia would result in sub-optimal **neurohormonal blockade**. - Stable renal impairment (Stage 3b CKD) is not an indication for dose reduction if the serum **creatinine rise** from baseline is less than 30%. *Stop empagliflozin as it may be contributing to hyperkalaemia and renal impairment* - **SGLT2 inhibitors** like empagliflozin actually provide **renoprotective** benefits and reduce the risk of more severe hyperkalemia when used with MRAs. - There is no clinical indication to stop this medication as it is indicated for both **HFrEF** and **type 2 diabetes** with CKD. *Stop tamsulosin as it may be causing orthostatic hypotension and reduce polypharmacy* - While **tamsulosin** can cause orthostatic hypotension, the patient's dizziness is occasional, and his overall symptom control is good. - Stopping an effective medication for **benign prostatic hyperplasia** (BPH) without a clear, overriding reason may worsen urinary symptoms, and dizziness could also stem from other cardiovascular medications.

Undifferentiated Symptoms UK Medical PG Question 5: Understanding the concept of 'diagnostic uncertainty' in managing undifferentiated symptoms in primary care involves recognizing that certain presentations cannot be immediately diagnosed. Which of the following statements best describes the evidence-based approach to managing diagnostic uncertainty?

• A. Immediate referral to secondary care is always appropriate when a diagnosis cannot be made in primary care to ensure patient safety
• B. Safety-netting with clear instructions for re-consultation if symptoms persist, worsen, or new features develop is an essential component of managing uncertainty (Correct Answer)
• C. Extensive investigation should be undertaken immediately to exclude all possible serious diagnoses before adopting a watch-and-wait approach
• D. Patients should be reassured that the absence of abnormal findings on initial tests means serious pathology is excluded and no follow-up is needed
• E. Empirical treatment should be started for the most likely diagnosis to avoid delays in management

Undifferentiated Symptoms Explanation: ***Safety-netting with clear instructions for re-consultation if symptoms persist, worsen, or new features develop is an essential component of managing uncertainty***- **Safety-netting** is an evidence-based strategy that allows for the management of **undifferentiated symptoms** by providing patients with clear, specific **red-flag symptoms** and a planned follow-up.- This approach maintains **patient safety** and utilizes the clinical tool of **time as a diagnostic test**, permitting the natural history of a condition to reveal itself without unnecessary harm.*Immediate referral to secondary care is always appropriate when a diagnosis cannot be made in primary care to ensure patient safety*- Primary care clinicians frequently manage **low-prevalence conditions** where immediate referral would lead to **over-medicalization** and unnecessary patient anxiety.- Most undifferentiated symptoms in primary care are **self-limiting** or benign, making immediate specialist referral an inefficient and potentially harmful use of resources.*Extensive investigation should be undertaken immediately to exclude all possible serious diagnoses before adopting a watch-and-wait approach*- Over-investigation increases the risk of **false positives** and **incidentalomas**, which may lead to invasive procedures that cause more harm than the original symptom.- A **judicious use of investigations** is preferred to avoid the cascades of care that arise from testing without sufficient clinical suspicion.*Patients should be reassured that the absence of abnormal findings on initial tests means serious pathology is excluded and no follow-up is needed*- Many serious conditions can present with **normal initial tests** because some pathologies only become detectable as the disease progresses over time.- Providing false reassurance without a plan for **re-evaluation** violates the principles of safety-netting and may lead to **delayed diagnoses** if symptoms evolve.*Empirical treatment should be started for the most likely diagnosis to avoid delays in management*- Initiating treatment without a diagnosis can **mask symptoms**, making it significantly more difficult to reach a definitive diagnosis later.- This approach exposes patients to potential **adverse drug reactions** and side effects that are unnecessary if the underlying cause is a self-limiting viral illness.

Undifferentiated Symptoms Flashcard 1 of 1

Question: What Genitourinary Differentials could cause Falls? 2

Answer: • Incontinence • UTIs